Please provide the article or its content so I can generate an SEO-friendly meta description based on your guidelines.

Lilly’s upfront offer for Adverum, the developer of a gene therapy for age-related macular degeneration, is less than the ...

Eli Lilly said on Friday it would acquire gene therapy developer Adverum Biotechnologies in a deal valued at up to $261.7 ...

Eli Lilly acquired Adverum, gaining access to Ixo-vec, a gene therapy for wet age-related macular degeneration. Read why I ...

Eli Lilly said on Friday it would acquire gene therapy developer Adverum Biotechnologies in a deal valued at up to $261.7 ...

Eli Lilly has agreed to acquire eye disease specialist Adverum Biotechnologies, bucking a recent trend of big pharma ...

Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related ...

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) to Eli Lilly and Company is fair to Adverum shareholders. Under the ...

Indianapolis: Eli Lilly and Company and Adverum Biotechnologies, Inc., a clinical-stage company, have announced a definitive ...

Eli Lilly and Company has agreed to acquire Adverum Biotechnologies Inc., a clinical-stage company pioneering the use of intravitreal gene therapy.

Eli Lilly plans to acquire a gene therapy developer that once planned a 200-job facility in Research Triangle Park.